EUVIMEDEUVIMED entdecken
Systematische ÜbersichtMetaanalyseOpen Access · CC BY-NC 4.0

Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials

Rafaela de Moraes-Souza, Regina Chahine Chater, Izabela Pera Calvi, Yasmin Mesquita, Rubiana Sarto, Izadora Lapenda, Lívia Figueiredo Pereira, Luana Moury, Pedro Herranz-Pinto

Clinical Drug Investigation · 2024

DOI: 10.1007/s40261-024-01368-w ↗

Kurz gefasst

Systematische Übersicht in der Zeitschrift Clinical Drug Investigation, 2024. Verfasst von Rafaela de Moraes-Souza und 8 weiteren Autor:innen. Beteiligte Einrichtung: Department of Dermatology, Faculty of Medicine, Autonomous University of Madrid, La Paz University Hospital, Madrid, Comunidad de Madrid, Spain. Hauptthemen laut MEDLINE: Aminopyridines, Benzamides, Psoriasis. Die Arbeit wurde bisher 5-mal zitiert (Crossref) und nennt 34 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Universidad Autónoma de Madrid.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BACKGROUND AND OBJECTIVE: Plaque psoriasis is commonly treated topically with glucocorticoids and vitamin D derivatives. However, potential side effects such as skin atrophy underscore the need for safe and effective alternative topical therapies. Recently, the US Food and Drug Administration (FDA) and Health Canada approved roflumilast 0.3% cream as an option for treating this disease. A systematic review and meta-analysis of randomized controlled trials (RCTs) was conducted to assess the efficacy and safety of topical roflumilast 0.3% compared with vehicle for plaque psoriasis. METHODS: PubMed, Embase, ClinicalTrials.gov, and Cochrane databases were searched from inception to 1 May 2024, assessing the outcomes of Investigator's Global Assessment (IGA) or body-IGA success (clear or almost clear status plus an at least 2-grade improvement from baseline), Psoriasis Area and Severity Index (PASI)-50, PASI-75, PASI-90, intertriginous-IGA success (clear or almost clear status on the intertriginous-IGA plus an at least 2-grade improvement from baseline), and adverse events (AEs). Statistical analysis was performed using Review Manager, R software, and RStudio. Heterogeneity was determined using the Cochran Q test and I2 statistics. RESULTS: Four RCTs were included, comprising a total of 1403 patients, of whom 885 (63.1%) received topical roflumilast 0.3% and 518 (36.9%) received vehicle. At week 8, the achievement of IGA or body-IGA success was significantly higher among those treated with topical roflumilast than in the vehicle group [relative risk (RR) 5.07; 95% confidence interval (CI) 3.55-7.23; p < 0.01]. Similar findings were observed at week 8 for PASI-50 (RR 2.73; 95% CI 2.27-3.29; p < 0.01), PASI-75 (RR 4.48; 95% CI 2.26-8.89; p < 0.01), and PASI-90 (RR 5.61; 95% CI 2.57-12.25; p < 0.01). Corresponding outcomes were found at weeks 2, 4, and 6. Additionally, a higher percentage of patients treated with topical roflumilast 0.3% once daily achieved intertriginous-IGA success, compared with those receiving vehicle, at week 8 (71.9% versus 20.5%; RR 3.32; 95% CI 2.11-5.22; p < 0.01), with similar findings at weeks 2, 4, and 6. While a significant difference was observed in the overall incidence of AEs between the topical roflumilast and vehicle groups, there was no difference in treatment-related AEs, serious AEs, or AEs leading to study discontinuation. CONCLUSION: These findings support the superiority of topical roflumilast 0.3% over vehicle and suggest its use as a valuable asset for the treatment of plaque psoriasis. PROTOCOL REGISTRATION: International Prospective Register of Systematic Reviews (PROSPERO), CRD42023456494.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

AminopyridinesBenzamidesPsoriasisHumansAdministration, TopicalCyclopropanesPhosphodiesterase 4 InhibitorsRandomized Controlled Trials as TopicTreatment Outcome

Substanzen

AminopyridinesBenzamidesCyclopropanesPhosphodiesterase 4 InhibitorsRoflumilast

Autor:innen und Institutionen

  • Department of Dermatology, Faculty of Medicine, Autonomous University of Madrid, La Paz University Hospital, Madrid, Comunidad de Madrid, Spain.
  • Division of Medicine, Albert Einstein Israeli Faculty of Health Sciences, São Paulo, São Paulo, Brazil.
  • Division of Medicine, Immanuel Kant Baltic Federal University, Kaliningrad, Kaliningrad Oblast, Russia.
  • Division of Medicine, Federal University of Rio de Janeiro, Macaé, Rio de Janeiro, Brazil.
  • Division of Medicine, Nevill Hall Hospital, Abergavenny, Monmouthshire, Wales.
  • Division of Medicine, Faculdade Pernambucana de Saúde, Recife, Pernambuco, Brazil.

Förderung

  • Universidad Autónoma de Madrid

Zitieren

APA

de Moraes-Souza, R., Chahine Chater, R., Pera Calvi, I., Mesquita, Y., Sarto, R., Lapenda, I., Figueiredo Pereira, L., Moury, L., & Herranz-Pinto, P. (2024). Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clinical Drug Investigation. https://doi.org/10.1007/s40261-024-01368-w

Vancouver

de Moraes-Souza R, Chahine Chater R, Pera Calvi I, Mesquita Y, Sarto R, Lapenda I, et al. Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. Clinical Drug Investigation. 2024. doi:10.1007/s40261-024-01368-w

BibTeX
@article{deMoraesSouza2024,
  author = {de Moraes-Souza, Rafaela and Chahine Chater, Regina and Pera Calvi, Izabela and Mesquita, Yasmin and Sarto, Rubiana and Lapenda, Izadora and Figueiredo Pereira, Lívia and Moury, Luana and Herranz-Pinto, Pedro},
  title = {Efficacy and Safety of Topical Roflumilast for the Treatment of Psoriasis: A Systematic Review and Meta-Analysis of Randomized Controlled Trials},
  journal = {Clinical Drug Investigation},
  year = {2024},
  doi = {10.1007/s40261-024-01368-w}
}
Kostenlos starten →